Innovative therapies for malignant brain tumors: the road to a tailored cure.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
30 06 2020
30 06 2020
Historique:
received:
30
05
2020
accepted:
01
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
29
6
2021
Statut:
epublish
Résumé
Immune tolerance, immune escape, neoangiogenesis, phenotypic changes, and glioma stem cells are all responsible for the resistance of malignant brain tumors to current therapies and persistent recurrence. The present study provides a panoramic view of innovative therapies for malignant brain tumors, especially glioblastoma, aimed at achieving a tailored approach. PubMed/Medline and ClinicalTrials.gov were the main sources of an extensive literature review in which "Regenerative Medicine," "Cell-Based Therapy," "Chemotherapy," "Vaccine," "Cell Engineering," "Immunotherapy, Active," "Immunotherapy, Adoptive," "Stem Cells," "Gene Therapy," "Target Therapy," "Brain Cancer," "Glioblastoma," and "Malignant Brain Tumor" were the search terms. Only articles in English published in the last 5 years were included. A further selection was made according to the quality of the studies and level of evidence. Cell-based and targeted therapies represent the newest frontiers of brain cancer treatment. Active and adoptive immunotherapies, stem cell therapies, and gene therapies represent a tremendous evolution in recent years due to many preclinical and clinical studies. Clinical trials have validated the effectiveness of antibody-based immunotherapies, including an in-depth study of bevacizumab, in combination with standard of care. Preclinical data highlights the role of vaccines, stem cells, and gene therapies to prevent recurrence. Monoclonal antibodies strengthen the first-line therapy for high grade gliomas. Vaccines, engineered cells, stem cells, and gene and targeted therapies are good candidates for second-line treatment of both newly diagnosed and recurrent gliomas. Further data are necessary to validate this tailored approach at the bedside.
Sections du résumé
BACKGROUND
Immune tolerance, immune escape, neoangiogenesis, phenotypic changes, and glioma stem cells are all responsible for the resistance of malignant brain tumors to current therapies and persistent recurrence. The present study provides a panoramic view of innovative therapies for malignant brain tumors, especially glioblastoma, aimed at achieving a tailored approach.
METHODS
PubMed/Medline and ClinicalTrials.gov were the main sources of an extensive literature review in which "Regenerative Medicine," "Cell-Based Therapy," "Chemotherapy," "Vaccine," "Cell Engineering," "Immunotherapy, Active," "Immunotherapy, Adoptive," "Stem Cells," "Gene Therapy," "Target Therapy," "Brain Cancer," "Glioblastoma," and "Malignant Brain Tumor" were the search terms. Only articles in English published in the last 5 years were included. A further selection was made according to the quality of the studies and level of evidence.
RESULTS
Cell-based and targeted therapies represent the newest frontiers of brain cancer treatment. Active and adoptive immunotherapies, stem cell therapies, and gene therapies represent a tremendous evolution in recent years due to many preclinical and clinical studies. Clinical trials have validated the effectiveness of antibody-based immunotherapies, including an in-depth study of bevacizumab, in combination with standard of care. Preclinical data highlights the role of vaccines, stem cells, and gene therapies to prevent recurrence.
CONCLUSION
Monoclonal antibodies strengthen the first-line therapy for high grade gliomas. Vaccines, engineered cells, stem cells, and gene and targeted therapies are good candidates for second-line treatment of both newly diagnosed and recurrent gliomas. Further data are necessary to validate this tailored approach at the bedside.
Identifiants
pubmed: 32608372
doi: 10.23750/abm.v91i7-S.9951
pmc: PMC7975829
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5-17Références
Neurology. 2006 Feb 28;66(4):587-9
pubmed: 16505319
Exp Cell Res. 2004 Apr 1;294(2):559-70
pubmed: 15023542
Heliyon. 2019 Nov 26;5(11):e02818
pubmed: 31844735
Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20150017
pubmed: 26416686
Ann Surg Oncol. 2008 Oct;15(10):2887-93
pubmed: 18636295
Science. 1997 Apr 4;276(5309):66-71
pubmed: 9082987
PLoS One. 2014 Dec 26;9(12):e116114
pubmed: 25541984
N Engl J Med. 2018 Jul 12;379(2):194-196
pubmed: 29943655
Cancer Res. 2013 Aug 1;73(15):4923-36
pubmed: 23796560
Lancet Oncol. 2006 May;7(5):392-401
pubmed: 16648043
Oncogene. 2005 May 12;24(21):3484-91
pubmed: 15735745
Clin Cancer Res. 2017 Jan 1;23(1):124-136
pubmed: 27358487
Childs Nerv Syst. 2008 Jun;24(6):773-6
pubmed: 18369643
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83
pubmed: 24045166
J Pediatr Endocrinol Metab. 2014 Jan;27(1-2):107-15
pubmed: 24025722
Dev Med Child Neurol. 2019 Sep;61(9):1101-1107
pubmed: 31175679
Gene Ther. 1996 Jun;3(6):491-5
pubmed: 8789798
J Headache Pain. 2014 Sep 01;15:57
pubmed: 25178699
Mol Ther. 2013 Nov;21(11):2087-101
pubmed: 23939024
Turk Neurosurg. 2019;29(6):875-886
pubmed: 31452176
Clin Cancer Res. 2016 Oct 1;22(19):4797-4806
pubmed: 27143690
Neuro Oncol. 2013 Apr;15(4):490-6
pubmed: 23328813
Nat Biotechnol. 2014 Apr;32(4):347-55
pubmed: 24584096
Surg Neurol Int. 2017 Jun 13;8:117
pubmed: 28680736
Expert Rev Vaccines. 2012 Feb;11(2):133-44
pubmed: 22309662
eNeurologicalSci. 2018 Nov 27;14:31-33
pubmed: 30555950
ACS Appl Mater Interfaces. 2015 Apr 1;7(12):6674-82
pubmed: 25751368
Int J Cancer. 2004 May 10;109(6):893-9
pubmed: 15027123
Neuro Oncol. 2018 Apr 9;20(5):674-686
pubmed: 29106665
Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67
pubmed: 30595200
J Clin Oncol. 2004 Jan 1;22(1):133-42
pubmed: 14638850
Cancer Res. 2003 Nov 1;63(21):7462-7
pubmed: 14612546
Acta Oncol. 2014 Jul;53(7):939-44
pubmed: 24456504
Recent Pat Inflamm Allergy Drug Discov. 2015;9(2):136-43
pubmed: 26256461
Cytotherapy. 2017 Mar;19(3):408-418
pubmed: 28109751
J Clin Oncol. 2019 Mar 20;37(9):741-750
pubmed: 30715997
J Clin Oncol. 2003 Jul 1;21(13):2508-18
pubmed: 12839017
Front Immunol. 2020 Feb 13;11:205
pubmed: 32117316
J Neurosurg. 2008 May;108(5):963-71
pubmed: 18447714
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
EMBO Mol Med. 2017 Sep;9(9):1183-1197
pubmed: 28765140
J Neurooncol. 2013 Aug;114(1):135-40
pubmed: 23686298
J Biol Chem. 2014 Dec 12;289(50):34595-600
pubmed: 25342742
Hum Vaccin Immunother. 2014;10(11):3139-45
pubmed: 25483653
Nature. 2015 Mar 19;519(7543):366-9
pubmed: 25762141
Front Oncol. 2015 Jan 29;5:5
pubmed: 25688333
Oncotarget. 2016 Sep 13;7(37):60245-60269
pubmed: 27533246
Neuro Oncol. 2014 Jan;16(2):274-9
pubmed: 24335700
Methods Mol Biol. 2007;399:199-213
pubmed: 18309934
J Neurooncol. 2010 Jan;96(2):219-30
pubmed: 19562254
Curr Cancer Drug Targets. 2017;17(3):290-296
pubmed: 28029074
Expert Rev Neurother. 2015;15(7):741-52
pubmed: 26027432
Science. 2011 Jul 15;333(6040):307
pubmed: 21700836
Cancer Immunol Immunother. 2013 Jan;62(1):125-35
pubmed: 22847020
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Front Oncol. 2020 Jan 17;9:1547
pubmed: 32010632
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3525-9
pubmed: 8622970
J Neurooncol. 2009 Mar;92(1):99-105
pubmed: 19018475
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Acta Neurochir Suppl. 2018;129:19-24
pubmed: 30171309
Neurosurg Clin N Am. 2012 Apr;23(2):289-95, ix
pubmed: 22440872
Cell Death Differ. 2008 Apr;15(4):718-29
pubmed: 18202704
Cancer Res. 2004 Aug 1;64(15):5347-54
pubmed: 15289341
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
pubmed: 23095881
Mol Ther. 2000 Feb;1(2):195-203
pubmed: 10933931
J Neurooncol. 2017 Jul;133(3):455-467
pubmed: 28527008
J Pediatr Surg. 2008 Nov;43(11):1998-2003
pubmed: 18970931
J Neurooncol. 2018 Nov;140(2):317-328
pubmed: 30073642
Neoplasia. 2018 Jan;20(1):25-31
pubmed: 29190492
Neuro Oncol. 2010 May;12(5):508-16
pubmed: 20406901
Arch Dis Child. 2019 Aug;104(8):768-774
pubmed: 30948362
Neuro Oncol. 2011 Dec;13(12):1339-48
pubmed: 21914639
Mol Ther. 2013 Mar;21(3):629-37
pubmed: 23070117
J Immunol. 2014 Dec 15;193(12):6192-206
pubmed: 25381437
Science. 2014 Nov 28;346(6213):1258096
pubmed: 25430774
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
Cancer Res. 2017 Dec 15;77(24):6795-6811
pubmed: 29247038
Surg Neurol Int. 2018 Jan 25;9:19
pubmed: 29497572
Sci Rep. 2018 Apr 30;8(1):6704
pubmed: 29712977
Eur J Surg Oncol. 2014 Mar;40(3):297-304
pubmed: 24411704
Ital J Pediatr. 2018 Apr 4;44(1):44
pubmed: 29618369
Immunol Rev. 2017 Mar;276(1):97-111
pubmed: 28258697
Acta Neurochir Suppl. 2018;129:25-31
pubmed: 30171310
Acta Neurochir Suppl. 2018;129:109-113
pubmed: 30171322
Clin Cancer Res. 2017 Nov 1;23(21):6650-6660
pubmed: 28751450
Asia Pac J Clin Oncol. 2016 Mar;12(1):e23-9
pubmed: 24571331
World Neurosurg. 2018 Aug;116:e340-e353
pubmed: 29751183
World Neurosurg. 2017 Sep;105:895-905
pubmed: 28559081
Int J Cancer. 2010 Mar 1;126(5):1206-15
pubmed: 19653275
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Am J Pathol. 2012 Oct;181(4):1126-41
pubmed: 22858156
Front Oncol. 2017 Jun 16;7:120
pubmed: 28670569
Clin Cancer Res. 2010 Jan 15;16(2):474-85
pubmed: 20068073